News and Media From Verici Dx

NewsMedia

Medicare National Payment Rate for Tutivia™ and Clarava™ Effective as of January 1, 2024

January 8, 2024

Verici Dx announces announces that the Centers for Medicare & Medicaid Services ("CMS") released the Clinical Laboratory Fee Schedule (“CLFS”) payment rate

Keep Reading

Verici Dx Clinical Laboratory achieves CAP accreditation

January 8, 2024

Verici Dx announces that its testing laboratory in Franklin, TN, has been accredited by the internationally recognised College of American Pathology (CAP)

Keep Reading

Tutivia™ validation study published in The American Journal of Transplantation

December 12, 2023

Verici Dx announces successful pivotal international validation study for TutiviaTM to improve patient outcomes

Keep Reading

ISO 27001 Information Security Certification Achieved

November 29, 2023

Verici Dx announces that it has attained the ISO 27001 certification for its Information Security Management System (“ISMS”).

Keep Reading

Verici Dx plc reaches a global licensing and commercialization agreement with Thermo Fisher Scientific

November 15, 2023

Agreement grants rights to further develop an assay for pre-transplant prognostic testing. Cardiff, U.K. (November 15, 2023) – Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced that it has signed an exclusive global licensing agreement with Thermo Fisher Scientific, the world leader in serving science, to further develop an assay for pre-transplant prognostic testing for risk of early kidney rejection.

Keep Reading

Clarava™ poster to be presented at ASN Kidney Week

November 2, 2023

Verici Dx announces announces international clinical validation study data to be presented at the largest global gathering of kidney health professionals

Keep Reading

Half-year report

September 29, 2023

Continuing to build the foundations for commercial success. Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces its unaudited interim results for the six months ended 30 June 2023. Operational highlights (including post-period end) Initial revenues following the commercial launch of our first product, Tutivia™, the Company’s post-transplant prognostic […]

Keep Reading

CLIA Certificate of Compliance update

July 20, 2023

US clinical laboratory now fully accredited in 49 states Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that further to the RNS dated 2 March 2023, the Company has received compliance authorisation for the operation of its commercial clinical laboratory testing in respect of samples from an additional […]

Keep Reading

Successful validation of Clarava™ from an international clinical study

July 3, 2023

Clarava™, a first-in-class pre-transplant prognostic test for risk of early kidney rejection, On track for US commercial launch by end of 2023 Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces successful validation results from its prospective, blinded, international multi-centre clinical validation study for Clarava™. Clarava™, is the first pre-transplant prognostic test to […]

Keep Reading

Proposed US pricing for Tutivia™

June 5, 2023

Medicare proposed gapfill median rate of $2,650 per test Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that a gapfill median rate of $2,650 has been proposed for Tutivia™ for kidney transplant rejection by the Centers for Medicare & Medicaid Services (“CMS”).Medicare is a national health insurance program […]

Keep Reading

1 2 3 … 8 Next »

Verici Dx CEO Sara Barrington on the In Vivo podcast

Sara Barrington, CEO of Verici Dx, spoke to the In Vivo podcast. During the discussion, Sara outlines the current challenges facing patients post-transplant, how Verici Dx addresses these challenges, and where the overall transplant market is headed, considering the rise of home dialysis and the potential future for xenotransplants.